CVS Health (NYSE:CVS – Get Free Report) issued an update on its third quarter 2024 earnings guidance on Friday morning. The company provided earnings per share guidance of 1.050-1.100 for the period, compared to the consensus earnings per share estimate of 1.700. The company issued revenue guidance of -. CVS Health also updated its Q3 guidance to $1.05-1.10 EPS.
CVS Health Stock Down 5.2 %
NYSE:CVS opened at $60.35 on Friday. The firm has a market capitalization of $75.76 billion, a P/E ratio of 10.61, a P/E/G ratio of 0.93 and a beta of 0.54. CVS Health has a 12-month low of $52.77 and a 12-month high of $83.25. The stock’s fifty day simple moving average is $59.80 and its 200-day simple moving average is $60.62. The company has a quick ratio of 0.66, a current ratio of 0.86 and a debt-to-equity ratio of 0.83.
CVS Health (NYSE:CVS – Get Free Report) last announced its earnings results on Wednesday, August 7th. The pharmacy operator reported $1.83 EPS for the quarter, topping the consensus estimate of $1.73 by $0.10. CVS Health had a net margin of 1.98% and a return on equity of 12.72%. The firm had revenue of $91.23 billion for the quarter, compared to the consensus estimate of $91.41 billion. During the same period last year, the company posted $2.21 EPS. The business’s quarterly revenue was up 2.6% on a year-over-year basis. Equities research analysts expect that CVS Health will post 6.51 earnings per share for the current year.
CVS Health Announces Dividend
Analyst Upgrades and Downgrades
Several brokerages recently commented on CVS. Royal Bank of Canada restated an “outperform” rating and set a $68.00 target price on shares of CVS Health in a report on Wednesday, September 4th. TD Cowen upgraded shares of CVS Health from a “hold” rating to a “buy” rating and raised their target price for the company from $59.00 to $85.00 in a research note on Friday, October 4th. Evercore ISI boosted their price target on CVS Health from $62.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Barclays upgraded CVS Health from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $63.00 to $82.00 in a research note on Thursday, October 10th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on CVS Health from $64.00 to $63.00 and set a “hold” rating for the company in a report on Friday, August 9th. Nine equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $75.26.
View Our Latest Analysis on CVS Health
CVS Health Company Profile
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Read More
- Five stocks we like better than CVS Health
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Misses and Beats: 3 Stocks That Are Moving Markets Right Now
- What is the Australian Securities Exchange (ASX)
- Cisco on the Rise: AI Potential and Analyst Upgrades Drive Gains
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- MarketBeat Week in Review – 10/14 – 10/18
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.